Another study showed that the mean tumor-to-background ratio (TBR) increased with dose (3.6 at 50 mg versus 4.3 at 100 mg) and was significantly higher in contrast-enhancing tumors than in nonenhancing ones (4.0±0.5 versus 1.2±0.3; p=0.02), confirming the feasibility of EGFR-targeted imaging.11 Here, EGFR is linked to neoplasm.